Clozaril Tapering Guide
clozapine
Boxed Warning
Severe neutropenia/agranulocytosis (REMS-required ANC monitoring), orthostatic hypotension/cardiovascular and respiratory effects, seizures, myocarditis and cardiomyopathy, increased mortality in elderly with dementia-related psychosis.
Overview
Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia and reduces suicide risk in schizophrenia. Reserved for treatment-resistant cases because of severe agranulocytosis risk requiring lifelong blood monitoring (REMS program).
12.5mg, 25mg, 50mg, 100mg, 200mg tablets; orally disintegrating
Tablets: 25mg, 100mg; ODT: 12.5mg, 25mg, 100mg, 150mg, 200mg; Oral suspension: 50mg/mL
Category B
Mechanism of Action
D2 antagonist (modest), strong 5-HT2A, M1, alpha-1, H1 antagonism. Broad receptor profile — drives both efficacy and side-effect burden.
Taper Notes
Very slow taper essential. Rebound psychosis on clozapine discontinuation can be more severe than original presentation. Coordinate with hematology and the REMS program.
Hyperbolic Tapering Guidance
Clozapine is unique — discontinuation should not be attempted without a clear plan and continuous mood/psychosis monitoring.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
1-3 days after stopping
1-2 weeks
4-8 weeks
Risk of supersensitivity psychosis after stopping is real and well-described
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Smoking cessation — increases clozapine levels (CYP1A2 induction loss)
- Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) — markedly increase levels
- Other agranulocytosis-risk drugs (carbamazepine) — contraindicated
Contraindications
- History of clozapine-induced agranulocytosis
- Active myeloproliferative disorder
- Uncontrolled epilepsy
Toxicity
Agranulocytosis (~1%), myocarditis, seizures (dose-dependent), severe constipation/ileus, hypersalivation, weight gain, metabolic syndrome, orthostasis, sedation, NMS.
Pharmacokinetics
ADME Profile
Hepatic via CYP1A2 (major), CYP3A4, CYP2D6.
~97%
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Clozaril (clozapine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D 2021 — A method for tapering antipsychotic treatment that may minimize the risk of relapse (Schizophrenia Bulletin)
- Tranter R, Healy D 1998 — Antipsychotic withdrawal symptoms: phenomenology and pathophysiology (Journal of Psychopharmacology)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Royal College of Psychiatrists — Antipsychotics — UK clinical guidance on antipsychotic prescribing and discontinuation
- Council for Evidence-Based Psychiatry (CEP UK) — Evidence-based critique of long-term antipsychotic prescribing
- Deprescribing.org — Antipsychotic deprescribing algorithm for insomnia and BPSD
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — antipsychotic tapering forum — Community archive of antipsychotic taper experiences
- Mad in America — antipsychotic archive — Independent journalism on antipsychotics and withdrawal
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- RxISK — adverse drug reaction reporting — Independent database of antipsychotic adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.